2. Search Result
Search Result
Results for "

Ruxolitinib

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-50856
    Ruxolitinib
    Maximum Cited Publications
    139 Publications Verification

    INCB18424

    		 JAK Autophagy Mitophagy Apoptosis Cancer
    Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .
    Ruxolitinib
  • HY-50856A
    Ruxolitinib (S enantiomer)
    4 Publications Verification

    S-Ruxolitinib; S-INCB18424

    		 JAK Cancer
    Ruxolitinib (S enantiomer) (S-Ruxolitinib) is the S-enantiomer of Ruxolitinib (HY-50856). Ruxolitinib (S enantiomer) is an orally active, potent JAK inhibitor .
    Ruxolitinib (S enantiomer)
  • HY-50858
    Ruxolitinib phosphate
    Maximum Cited Publications
    139 Publications Verification

    INCB018424 phosphate

    		 JAK Autophagy Mitophagy Cancer
    Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.
    Ruxolitinib phosphate
  • HY-50856S
    Deuruxolitinib

    CTP-543; Ruxolitinib d8; Deuterated Ruxolitinib

    		 JAK Inflammation/Immunology
    Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I) .
    Deuruxolitinib
  • HY-W062703S1
    (Rac)-Ruxolitinib-d8

    (Rac)-INCB18424-d8; Ruxotinib racemate-d8

    		 Isotope-Labeled Compounds Others
    (Rac)-Ruxolitinib-d8 is deuterium labeled (Rac)-Ruxolitinib.
    (Rac)-Ruxolitinib-d8
  • HY-151902
    SJ988497

    		PROTACs JAK Cancer
    SJ988497 is a PROTAC JAK2 degrader. SJ988497 potently inhibits CRLF2-rearranged (CRLF2r) cell proliferation and degrades the CRBN neosubstrate GSPT1. SJ988497 consists of a Ruxolitinib (HY-50856) derivative, linker, and CRBN ligand Pomalidomide. SJ988497 can be used in the research of acute lymphoblastic leukemia (ALL) .
    SJ988497
  • HY-W059210
    Ruxolitinib impurity-1

    		Biochemical Assay Reagents Others
    Ruxolitinib impurity-1 is the impurity of Ruxolitinib (HY-50856), which can be used safety analysis of Ruxolitinib therapy .
    Ruxolitinib impurity-1
  • HY-50856R
    Ruxolitinib (Standard)

    		JAK Autophagy Mitophagy Apoptosis Cancer
    Ruxolitinib (Standard) is the analytical standard of Ruxolitinib. This product is intended for research and analytical applications. Ruxolitinib (INCB18424) is a potent and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .
    Ruxolitinib (Standard)
  • HY-50859
    Ruxolitinib sulfate

    INCB018424 sulfate

    		 JAK Autophagy Cancer
    Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.
    Ruxolitinib sulfate
  • HY-W062703S
    (Rac)-Ruxolitinib-d9

    (Rac)-INCB18424-d9; Ruxotinib racemate-d9

    		 Isotope-Labeled Compounds JAK Cancer
    (Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor .
    (Rac)-Ruxolitinib-d9

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: